CN Mobile Logo


Multiple Myeloma

Multiple Myeloma

The FDA approved the proteasome inhibitor carfilzomib for the treatment of multiple myeloma, when used in combination with lenalidomide and dexamethasone.

Treatment with carfilzomib plus lenalidomide and dexamethasone resulted in high rates of minimal residual disease negativity in patients with newly diagnosed or smoldering high-risk multiple myeloma.

Use of a VD regimen alone to treat patients with transplant-ineligible multiple myeloma was not inferior to VTD or VMP regimens, according to the UPFRONT trial.

Zoledronic acid did not have any antitumor effect in asymptomatic multiple myeloma patients in relapse, but did delay symptomatic progression and bone disease.

Treatment with lenalidomide and the HDAC inhibitor vorinostat may be effective as a maintenance therapy in multiple myeloma patients after autologous transplant.

We discuss some of the anticipated multiple myeloma trials with Sagar Lonial, MD, ahead of the 2015 American Society of Clinical Oncology Annual Meeting.

Autologous stem cell transplant led to significantly longer overall survival than non-transplant strategies in a cohort of elderly patients with multiple myeloma.


Subscribe to Multiple Myeloma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.